Pharvaris has an FDA review date for deucrictibant, but can it stand out?
Find out how Pharvaris’ deucrictibant could reshape oral treatment options for hereditary angioedema attacks.
Pharma & Biotech
Pharma & Biotech
What Chiesi’s $1.9bn KalVista deal reveals about the next phase of rare disease consolidation
Rare disease M&A is shifting from science risk to launch execution. Chiesi’s KalVista deal puts oral HAE therapy at the center.
Pharma & Biotech
Will pediatric KONFIDENT-KID data accelerate KalVista’s sebetralstat approval in hereditary angioedema?
KalVista's sebetralstat pediatric trial data heads to Madrid. What it means for the HAE on-demand market and a 2026 FDA filing. Read the analysis.
Pharma & Biotech
Can KalVista’s refill-led EKTERLY growth signal a new standard in on-demand HAE care?
KalVista’s oral HAE drug EKTERLY hit $49M in 2025 sales. Discover what strong refill demand and global expansion mean for rare disease treatment models.